|1.||Ryan, Anderson J: 12 articles (11/2007 - 06/2002)|
|2.||Robinson, Simon P: 8 articles (09/2015 - 03/2004)|
|3.||Blakey, David C: 8 articles (05/2005 - 06/2002)|
|4.||Waterton, John C: 6 articles (11/2007 - 03/2004)|
|5.||Siemann, Dietmar W: 6 articles (11/2005 - 05/2002)|
|6.||Griffiths, John R: 5 articles (11/2007 - 03/2004)|
|7.||Yu, Jie: 4 articles (12/2013 - 08/2010)|
|8.||Marchal, Guy: 4 articles (12/2013 - 08/2010)|
|9.||Chen, Feng: 4 articles (12/2013 - 08/2010)|
|10.||Ni, Yicheng: 4 articles (01/2012 - 08/2010)|
02/15/2006 - "Clonogenic cell survival data indicated that ZD6126 was less effective in tumors with high IFP values (>25 mm Hg). "
11/01/2004 - "Combination with ZD6126 was regarded as more promising in BSH-BNCT than BPA-BNCT, and more effective for enhancing the sensitivity of the Q tumor cells than that of the total tumor cells. "
07/01/2005 - "The efficacy of ZD6126 was investigated in large vs. small tumors in a variety of animal models. "
02/15/2006 - "This study examined the effect of ZD6126 on tumor IFP and the response of tumors with different IFP levels to ZD6126. "
06/01/2004 - "The aim of the study reported here was to assess the ability of dynamic contrast enhanced magnetic resonance imaging (MRI) to measure the antivascular effects of ZD6126 in tumors. "
02/09/2004 - "ZD6126 also led to a significant decrease in the incidence of peritoneal carcinomatosis (10 out of 12 controls, vs one out of 12 ZD6126) (P<0.01). "
11/15/2003 - "Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response."
11/15/2003 - "The aim of this study was to investigate the pathophysiologic effects induced by the novel vascular targeting agent ZD6126 in a C3H mouse mammary carcinoma and to evaluate the agent's ability to inhibit tumor growth either when given alone or in combination with radiation. "
02/09/2004 - "ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer."
11/01/2005 - "The antitumor efficacy of combination therapy of the vascular disrupting agent ZD6126 and antiangiogenic agent ZD6474 was evaluated in the models of human colorectal (HT29) and ovarian carcinoma (OW1). "
|3.||Sarcoma (Soft Tissue Sarcoma)
07/01/2005 - "Detailed evaluation of KHT sarcomas treated with ZD6126 showed a reduction in patent tumor blood vessels that was approximately 20% in small (<0.3 g) vs. >90% in large (>1.0 g) tumors. "
07/01/2005 - "To examine the impact of tumor size on the extent of enhancement of radiation efficacy by ZD6126, KHT sarcomas of three different sizes were irradiated locally with a range of radiation doses, and cell survival was determined. "
07/01/2005 - "Histologic assessment revealed that the extent of tumor necrosis after ZD6126 treatment, although minimal in small KHT sarcomas, became more extensive with increasing tumor size. "
05/01/2002 - "The present results demonstrated that in the KHT sarcoma, ZD6126 caused rapid tumor vascular shutdown, induction of central tumor necrosis, tumor cell death secondary to ischemia, and enhancement of the antitumor effects of radiation therapy."
05/01/2002 - "The aim of this study was to evaluate the antitumor efficacy of the novel vascular targeting agent ZD6126 (N-acetylcochinol-O-phosphate) in the rodent KHT sarcoma model, either alone or in combination with single- or fractionated-dose radiation therapy. "
|4.||Melanoma (Melanoma, Malignant)
10/21/2008 - "The altered pharmacokinetics and tissue distribution profiles of both liposomal ZD6126 formulations resulted both in single-dose and multiple-dose regimes, in improved therapeutic efficacy in established murine B16.F10 melanomas compared with free ZD6126. "
10/21/2008 - "Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma."
11/15/2002 - "Volumetric HFD imaging of established melanomas detected a significant reduction in blood flow 4 h after injection of the tumor vascular targeting agent ZD6126 followed by a recovery of flow by 24 h after injection. "
03/01/2007 - "The study also included an assessment of tumour necrosis following administration of a single intravenous dose of non-labelled ZD6126 at 200 mgkg(-1). "
04/02/2014 - "In contrast, ZD6126 induced a significant decrease in the tumour-averaged |G*| (P<0.01), Gd (P<0.01) and Gl (P<0.05), and this was associated with histologically confirmed central necrosis. "
10/08/2007 - "ZD6126 given 2 or 24 h after PTX showed no significant benefit, a result that was attributed to a protective effect of PTX against ZD6126-induced vascular damage and tumour necrosis, a hallmark of VDA activity. "
03/01/2006 - "Whilst pBAN2R tumour necrosis increased in a dose-dependent manner, significant at 100 and 200 mg/kg ZD6126 (P < 0.05), intermediate doses did not induce a similar degree of necrosis in clone iNOS-19 tumours. "
02/09/2004 - "Histological analysis of tumours revealed large regions of central necrosis in the treated group, as well as a dramatic increase in tumour cell apoptosis (7.4-fold increase (P<0.001)), consistent with the vascular-targeting activity of ZD6126. "
|3.||N- (4- bromo- 2- fluorophenyl)- 6- methoxy- 7- ((1- methylpiperidin- 4- yl)methoxy)quinazolin- 4- amine (ZD6474)
|4.||glucuronyl glucosamine glycan sulfate (Vessel)
|5.||combretastatin A-4 (combretastatin A4)
|7.||Choline (Choline Chloride)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Boron Neutron Capture Therapy